The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
Caris Life Sciences
Offers molecular profiling services to identify precise therapeutic options for cancer patients.
What they do
Caris Life Sciences delivers comprehensive molecular profiling services that analyze DNA, RNA, and proteins from tumor biopsies. Oncologists use these genomic profiling results to match patients with precise, targeted therapies and relevant clinical trials based on their individual cancer profiles.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Growth
- Headquarters
- Irving, United States
- Region
- North America
- Founded
- 2008
- Total funding
- $1.7B raised
Notable investors: Sixth Street Partners, T. Rowe Price Associates, Silver Lake, Fidelity Management & Research Company.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
Beyond HER2 and TROP2: How AbbVie's c-Met Top1i Antibody-Drug Conjugate Earned Two Breakthrough Designations
Dr. Dereck Mush, MD, MBA
The Radiopharmaceutical Infrastructure Playbook: Why Telix's FDA Approval for Pixclara Redefines Neuro-Oncology Diagnostics and Theranostics
Dr. Dereck Mush, MD, MBA
The Great Directory Rollup: How H1 Is Building the Single Source of Truth for Provider Networks
Dr. Dereck Mush, MD, MBA